首页> International Journal of Cancer =: Journal International du Cancer> Molecular alterations and poziotinib efficacy, a pan‐HER inhibitor, in human epidermal growth factor receptor 2 (HER2)‐positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2‐positive breast cancer patients

Molecular alterations and poziotinib efficacy, a pan‐HER inhibitor, in human epidermal growth factor receptor 2 (HER2)‐positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2‐positive breast cancer patients

导出原文传递

翻译打印收藏纠错

第一作者： Kim Ji‐Yeon

作者： Kim Ji‐Yeon ^[1] ; Lee Eunjin ^[2] ; Park Kyunghee ^[3] ; Jung Hae Hyun ^[4] ; Park Woong‐Yang ^[5] ; Lee Kyung‐Hun ^[6] ; Sohn Joohyuk ^[7] ; Lee Keun Seok ^[8] ; Jung Kyung Hae ^[9] ; Kim Jee Hyun ; Lee Ki Hyeong ; Im Seock‐Ah ; Park Yeon Hee

作者单位： Samsung Advanced Institute for Health Sciences and TechnologySungkyunkwan University School of ^[1] Division of Hematology‐Oncology, Department of Internal MedicineSeoul National University Hospital ^[2] Department of Oncology, Asan Medical CenterUniversity of Ulsan College of MedicineSeoul,South Korea ^[3] Department of Internal MedicineChungbuk National University HospitalCheongju,South Korea ^[4] Department of Internal MedicineYonsei Cancer CenterSeoul,South Korea ^[5] Samsung Genome Institute, Samsung Medical CenterSungkyunkwan University School of MedicineSeoul ^[6] Department of Internal MedicineSeoul National University Bundang Hospital, Seoul National ^[7] Center for Breast CancerNational Cancer Center HospitalGoyang,South Korea ^[8] Division of Hematology‐Oncology, Department of Medicine, Samsung Medical CenterSungkyunkwan ^[9]

关键词 metastatic breast cancer HER2‐positive poziotinib biomarker targeted deep sequencing

发布时间 2019-12-11

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交